April 2023 in “Journal of Investigative Dermatology” Trichohyalin in hair can trigger immune attacks in alopecia areata.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
15 citations
,
February 2015 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Dermoscopy helps accurately diagnose temporal triangular alopecia, avoiding unnecessary treatments.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
January 2024 in “Archives of Endocrinology and Metabolism” A new gene mutation causes insulin resistance in a girl and her mother.
October 2025 in “International Journal of Risk & Safety in Medicine” Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
December 2023 in “Journal of Investigative Dermatology” A specific type of immune cell plays a key role in causing alopecia areata and could be a target for treatment.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
93 citations
,
May 2002 in “Journal of Investigative Dermatology” Overexpressing thrombospondin-1 in mice skin prevents UVB-induced skin damage.
April 2023 in “Journal of Investigative Dermatology” Mast cells and the CB1 receptor may be key in causing IgA vasculitis.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
10 citations
,
March 2022 in “Frontiers in Oncology” HOTTIP and miR-10b contribute to glioma therapy resistance by affecting cell behavior, suggesting they could be targets for treatment.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
1 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” TYK2 inhibitors show promise for treating cancer and autoimmune disorders.
April 2015 in “Plastic and Reconstructive Surgery” TLR3 activation helps improve skin and hair follicle healing in mice.
1 citations
,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
1 citations
,
February 2025 in “Journal of the Neurological Sciences” Beta-trace protein may help diagnose and predict treatment response in certain nerve disorders.
April 2018 in “Journal of Investigative Dermatology” The role of γδT-cells in causing alopecia areata remains unclear.
5 citations
,
June 2015 in “The Journal of Dermatology” HTLV-1-associated lichenoid dermatitis (HALD) is linked to an immune response against HTLV-1-infected cells.
33 citations
,
June 2007 in “Gene Expression Patterns” CTIP2 may help in skin development and maintenance.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
32 citations
,
January 2012 in “Clinical & Developmental Immunology” Targeting CD200 could be a new treatment for rheumatoid arthritis.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
April 2023 in “Journal of Investigative Dermatology” Higher PD-1 levels are linked to fewer immune cells in hair follicles in alopecia areata.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
April 2025 in “Journal of Diabetes & Metabolic Disorders” Monitoring TGF-β and linc-PINT expression may help identify and treat high-risk heart arrhythmia patients.